PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of corrspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
Clin Orthop Relat Res. Apr 2010; 468(4): 1120–1128.
Published online Sep 16, 2009. doi:  10.1007/s11999-009-1100-7
PMCID: PMC2835602
Fine Needle Aspiration for Clinical Triage of Extremity Soft Tissue Masses
Vincent Y. Ng, MD,corresponding author1 Kristen Thomas, MD,1 Martha Crist, RN,1 Paul E. Wakely, Jr., MD,2 and Joel Mayerson, MD1
1Department of Orthopaedics, Ohio State University Medical Center, 1050 Doan Hall, 410 West 10th Avenue, Columbus, OH 43210 USA
2Department of Pathology, Ohio State University Medical Center, Columbus, OH USA
Vincent Y. Ng, Vincent.Ng/at/osumc.edu, vincent_y_ng/at/yahoo.com.
corresponding authorCorresponding author.
Received February 7, 2009; Accepted August 31, 2009.
Background
Fine needle aspiration cytology (FNAC) is a rapid and low-morbid alternative to open biopsy or needle core biopsy for soft tissue masses. Numerous reports describe its use with metastatic or recurrent lesions, but FNAC is less accepted for primary lesions.
Questions/Purposes
We wished (1) to estimate the sensitivity, specificity, and positive and negative predictive values of FNAC for diagnosing malignancy; (2) to estimate the accuracy of subtyping and grading.
Methods
We retrospectively examined the diagnostic accuracy and clinical effectiveness of office-based FNAC performed by a trained pathologist on 213 females and 219 males (mean age, 51.8 years) who presented with a palpable soft tissue mass to one musculoskeletal oncology clinic between 2002 and 2008.
Results
The FNAC was reported as benign in 62.0%, indeterminate in 8.1%, and malignant in 29.9%. A second technique, such as needle core biopsy or open biopsy, was performed for 24.8% of lesions before a definitive treatment plan was rendered. Final tissue confirmation by open biopsy or resection was available for 52.2% of benign FNAC and 78.3% of malignant FNAC. Sensitivity, specificity, and positive and negative predictive values for detecting malignancy with either histopathologic confirmation or clinical followup were 89.2%, 89.8%, 96.1%, and 98.1%. There were seven sampling and nine interpretation FNAC errors in determining the nature of the lesion. Subtyping and grading for malignant lesions were 77.2% and 95.2% accurate, respectively.
Conclusions
FNAC is effective for initial triage and treatment selection at tertiary referral centers with close collaboration among the surgeon, pathologist, and radiologist.
Level of Evidence
Level II, diagnostic study. See the Guidelines for Authors for a complete description of levels of evidence.
Soft tissue sarcomas comprise 1% or less of all adult malignancies [5, 7]. In 2008, an estimated 10,000 Americans were diagnosed with a soft tissue sarcoma and approximately 3500 will die from it [12]. Orthopaedic oncology is a highly specialized field and improper management of these patients can result in unnecessary amputations and mortality [31]. Long-standing recommendations have been in place to refer all patients with suspicious musculoskeletal lesions to a high-volume tertiary care center for biopsy and definitive treatment [18]. Although traditional open incisional biopsies remain the diagnostic gold standard, less invasive methods such as needle core biopsy (NCB) and, more recently, fine needle aspiration (FNA) have emerged [35].
FNAC has been an integral part of the highly centralized care for patients with sarcoma in Scandinavian countries for many years [1, 3, 7, 8, 33, 34, 38]. Although FNAC generally is accepted at musculoskeletal oncology centers in the United States for documentation of metastases and local recurrences, especially if prior samples are available for comparison, its role in the evaluation of primary soft tissue sarcomas remains controversial and limited [29, 37, 39]. Rubin et al. suggested FNAC can be a valuable and cost-effective tool in expediting the care of patients with breast cancer without incurring the risks or delay of an open surgical procedure [27]. Performed bedside, it provides results within 30 minutes and can facilitate additional staging or treatment decisions during the initial clinic visit. Although FNAC reliably distinguishes mesenchymal from metastatic tumors, malignant from benign lesions, and high- from low-grade sarcomas, it has been criticized for its inability to precisely subtype sarcomas [9]. FNAC is not without potential pitfalls such as sampling error, failure of ancillary techniques, and low cellular yield [10, 24]. Nevertheless, because treatment decisions for sarcomas usually are based on size, location, and grade, some authors support FNAC as a primary modality to provide the necessary information to proceed with care [15, 29]. Benign characteristics on FNAC, in addition to a nonaggressive clinical presentation and benign radiographic features, can provide clinicians the confidence to observe such lesions. If malignancy is detected on cytology, chemotherapy, surgical excision, or additional staging studies can be planned without the need for additional biopsy.
Successful FNAC is contingent on two main factors: an experienced cytopathologist and close collaboration between the orthopaedic oncologist and the pathologist [11, 17]. For the past 8 years we have had such a situation, allowing for collection of a large database. A previous report from our institution suggested high reliability of FNAC, but included bone lesions and was limited to high-grade sarcomas [9]. We presumed FNAC would be an effective diagnostic tool for triaging patients presenting with a palpable soft tissue mass.
The purpose of the current study therefore was (1) to estimate the sensitivity, specificity, and positive and negative predictive values of FNAC for diagnosing malignancy; (2) to estimate the accuracy of subtyping and grading; (3) to determine the number of patients definitively treated based on FNAC and the clinicoradiographic presentation without additional diagnostic biopsy; and (4) to determine whether the cases in which a false-positive or false-negative error occurred were a result of interpretive error by the pathologist or sampling error by the FNA.
We retrospectively searched the medical records of all patients seen by the primary musculoskeletal oncologist (JM) at the adult office of the Arthur G. James Comprehensive Cancer Center at The Ohio State University between September 2002 and April 2008 to identify patients who received a FNA. The study group included only patients with soft tissue masses that were palpable on physical examination and that did not require radiographic guidance for FNA. Results of all FNAC specimens were interpreted by the head cytopathologist (PEW) or another experienced musculoskeletal pathologist (CM). Pathology reports from open biopsies and mass resections were accepted from all attending physicians in the pathology department. We believe FNAC plays a different role in the management of pediatric soft tissue sarcomas, and we therefore excluded patients seen in the pediatric office. Because of the specific chemotherapeutic protocols for Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma, histologic subtyping is necessary for appropriate selection of therapy. FNAC is more accurate in pediatric sarcomas in this regard [15]. We identified 459 cases of FNA. Twenty of these (4%) were excluded because the FNAC had been interpreted by a nonmusculoskeletal pathologist. Seven were excluded because the patient did not have definitive tissue verification of their FNA, did not return for followup, and could not be reached by telephone. The final study group consisted of 432 FNAs performed on 213 male and 219 female patients (Fig. 1). The mean age of the patients at the time of FNA was 51.8 years (range, 13–91 years). The most common locations were the thigh (107), leg (57), knee (37), arm (34), hand and fingers (28), forearm (24), foot and ankle (40), shoulder (23), and back (11). The FNAC diagnosis was benign in 268 of 432 (62.0%) cases, malignant in 129 (29.9%), and nondiagnostic or indeterminate in 35 (8.1%) (Fig. 1). The mean ages in each group were 48.7 years, 58.3 years, and 51.4 years, respectively. Proceedings were in accordance with the approved Ohio State University Institutional Review Board, application 2003C0058.
Fig. 1
Fig. 1
The study design is shown in this flow chart. Bx = biopsy; prn = as needed.
In all cases, a pathologist discussed clinicoradiographic findings with the surgeon, examined the patient, and performed a percutaneous FNA. One-, 1.5-, or 2-inch long 21- or 22-gauge needles connected to a 20-mL syringe was inserted without local anesthesia at the apex of the lesion or at a location specified by the orthopaedic oncologist to optimize future resection. Using firm suction and short, rapid strokes, an average of three separate passes was made. With each pass, the needle was angled in a different direction to sample as much of the mass as possible. Aspirated material was expelled onto glass slides and a second glass slide was used to make conventional smears. The needle was rinsed in a balanced salt solution after each pass for additional study: flow cytometry, paraffin-embedded cell block, or fluorescent in situ hybridization. For initial assessment, several slides were air-dried and stained with a Romanowsky stain. The remainder subsequently was rehydrated and stained using a modified Papanicolaou method. Within 20 minutes, a preliminary reading was rendered.
All pathology reports for tissue specimens acquired from open biopsies or resections were compared with the initial FNAC findings. Because the reliability of NCB compared with FNAC is controversial, NCB was not used for definitive verification of FNAC for the purposes of this study [4, 8]. Subtyping and cytomorphologic groupings were based on the recommendations of Kilpatrick et al. [14, 15] and Singh et al. [29] and Fletcher et al. for the Association of Directors of Anatomic and Surgical Pathology (ADASP) [10] (Table 1).
Table 1
Table 1
Grading of soft tissue sarcomas based on subtype/cytomorphologic grouping on fine needle aspiration cytology*
All decisions to proceed with definitive treatment or to perform a secondary biopsy were made by the primary musculoskeletal oncologist (JM) based on clinical judgment, radiologic findings, and cytologic findings. Rarely was a repeat FNA performed if the initial FNAC was nondiagnostic.
For patients who did not have histopathologic followup of a benign FNAC, attempts were made for this study to contact them or their primary physician by telephone to detect any potential misdiagnoses. For the cases in which the FNAC report was discrepant from the final pathology report, the head musculoskeletal pathologist (PEW) reviewed the cytology slides and compared them with the definitive tissue sample. Error was classified as sampling error if the FNAC slide did not contain material indicative of the actual pathology. Otherwise, it was deemed an interpretive error.
In the benign FNAC group (Table 2), 123 of 268 (46%) patients had surgical removal of their soft tissue mass. The other 145 were managed nonoperatively and were instructed either to follow up on an as-needed basis or to return for repeat imaging and serial examination. For patients told to follow up as needed, successful telephone contact was made at an average of 3.2 years.
Table 2
Table 2
Summary of the benign FNAC diagnoses
In the indeterminate FNAC group, 19 of the 35 patients had surgical removal of their mass; 16 received nonoperative management. Of these, 25 were benign (70.6%), four were high-grade malignant (11.8%), three were low-grade malignant (8.8%), and three were nongraded malignant (8.8%).
In the malignant FNAC group of 129 patients, there were 59 high-grade sarcomas, three and nine of which were metastases and local recurrences. There were 14 low-grade primary sarcomas and four low-grade recurrent sarcomas (Table 3). A subtype or cytomorphologic group and grade were rendered in 88 of 108 (81.5%) and 77 of 108 (71.3%) sarcomas, respectively.
Table 3
Table 3
Summary of malignant FNAC diagnoses
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for all patients who had FNAC (including those with indeterminate reports). These values were reported for patients with histopathologic confirmation and patients with either histopathologic confirmation or clinical followup. The accuracy of grading and subtyping malignant lesions was calculated based on cases with a FNA diagnosis and histopathologic confirmation. The number of patients treated after FNA without additional biopsy and the number of nondiagnostic FNAs were reported as percentages of the total FNA cases.
For patients with definitive tissue verification, the sensitivity and specificity for detecting malignancy with FNAC were 88.9% and 84.4%, respectively. The PPV was 95.1% and the NPV was 96.4%. If the cases without definitive tissue verification (ie, the benign FNAC cases managed nonoperatively and the malignant FNAC cases referred to oncology or hospice) are accepted as benign and malignant, the sensitivity, specificity, PPV and NPV improved to 89.2%, 89.8%, 96.1%, and 98.1% (Table 4). One hundred forty of the 268 (52.2%) patients with a benign lesion had a subsequent definitive tissue diagnosis after the initial benign FNA through open incisional biopsy, irrigation and débridement, or resection. Of these, 134 of the 140 masses (96%) were confirmed as benign and six were malignant neoplasms (Fig. 1). Of the 101 FNAC cases diagnosed as malignant with tissue verification, 96 (95%) were identified correctly as malignant. There were five false-positives for malignancy, two instances of overgrading, two sarcomas mistaken for lymphoma, and one rare spindle cell neoplasm reported as melanoma. Eleven of the 19 cases diagnosed with FNAC as locally recurrent sarcoma were after radiation in addition to prior surgical removal. There were no false positives, false negatives, or indeterminate FNACs for recurrent sarcoma.
Table 4
Table 4
Summary of FNAC and final diagnoses
For patients who had subsequent open biopsy or eventual resection, the subtyping and grading of malignant lesions, when provided by FNAC, were 77.2% and 95.2% accurate, respectively. For the 77 cases in which a sarcoma grade was provided by the FNAC, 60 were correct, three were incorrect, and 14 did not have final tissue verification. For the 88 cases in which a subtype was given, 61 were correct, 18 were incorrect, and nine were unverified.
Overall, 24.8% of patients required a secondary biopsy before pursuing a definitive treatment plan (Table 5). The nature of the lesion was indeterminate or the FNAC was inadequate in 8.1% of the cases. Among the 268 cases of benign FNAC, definitive treatment was rendered in 218 (81.3%) based on the FNAC alone. An open biopsy, NCB, or intraoperative frozen section was performed in the remaining 50 (18.6%) patients. No malignant degeneration or questionable change in the mass was reported by any patient or outside physician on telephone followup. In the indeterminate FNAC group, the definite treatment plan was based in the FNAC in 15 of the 35 patients (42.9%), while 20 of 35 (57.1%) required an additional open biopsy, NCB, or intraoperative frozen section. In 27 of 35 (77.1%) cases, final tissue verification was available from either open incisional biopsy or definitive resection. Thirty-two of 129 (24.8%) patients with initially malignant FNAC required a separate open biopsy, NCB, repeat FNA, or CT-guided biopsy before definitive treatment could ensue. Intraoperative biopsy during surgical resection was performed in an additional five patients. One hundred one of 129 (78.3%) patients had subsequent tissue diagnosis after the initial malignant FNA through open incisional biopsy or definitive resection. The remaining patients (28), 18 of whom were diagnosed with recurrent or metastatic sarcoma or lymphoma, were referred to oncology or hospice without additional histopathologic confirmation.
Table 5
Table 5
Number and type of secondary biopsies performed after initial FNAC
Retrospective analysis of the false positive and false negative cases revealed seven sampling errors and nine interpretation errors (Table 6).
Table 6
Table 6
Summary of cases with major FNA discrepancies
The majority of patients seen at the relatively few musculoskeletal oncology centers across America travel far from home to receive specialized care [31]. Although open incisional biopsy remains the diagnostic gold standard by providing ample tissue specimen, visual confirmation of accurate sampling, and full histologic architecture, it has substantial drawbacks [39]. Unlike a surgical procedure which incurs the risk of anesthetic complications, wound healing problems, infection, and tumor seeding, FNA is relatively painless, has rare complications, provides expedient patient triage, and is more cost effective [2, 15, 20, 21, 27, 30, 36, 37]. Compared with NCB, FNA is less expensive and less invasive, can sample a lesion more extensively, and provides quicker results [39]. The aim of this study was to determine the ability of FNAC to detect, grade, and subtype malignancy in patients presenting with palpable soft tissue masses. The rate of nondiagnostic FNAs and the effectiveness of FNAC to direct treatment options without secondary biopsy also were evaluated. In cases in which the nature of the lesion was diagnosed incorrectly by FNAC, the type of error, sampling or interpretive, was recorded.
There are several weaknesses in this study. First, because excising every benign lesion is impractical and unnecessary in many instances, not all benign FNAs had histopathologic confirmation. Nevertheless, clinical followup or telephone contact with patients or outside physicians verified that no symptoms concerning for a malignancy arose in subsequent years. Second, the determination of interpretation versus sampling error for discrepant cases was performed retrospectively by the same cytopathologist who rendered the initial FNAC diagnosis. Although this raises the possibility of bias and repeat interpretive error, the larger histopathologic specimen provided by definitive resection or open biopsy allowed for easy objective retrospective comparison.
The sensitivity, specificity, and PPV and NPV of FNAC in this study were comparable to published rates (Table 7). Although predictive values are affected primarily by false positive and negative cases, sensitivity and specificity are decreased by indeterminate FNACs as well. Close interdisciplinary collaboration and constant vigilance by the surgeon can help prevent adverse patient outcomes attributable to incorrect FNAC. It was suggested that for cytopathologists of all levels of experience, knowledge of the patients’ clinical background increased the proportion of correct diagnoses and accuracy of classification [17].
Table 7
Table 7
Literature review of FNAC for soft tissue masses
The rate of nondiagnostic FNA samples in this study compared favorably with rates in previous studies (Table 7). The relatively small sample size produced by FNA combined with the subtle spectrum from benign to low-grade to high-grade lesions can undermine the confidence of many pathologists to render a definitive diagnosis. Without an experienced on-site cytopathologist to interpret the FNAC and determine whether an additional specimen is necessary, many of the advantages afforded by FNAC are lost [21]. It can be difficult to collect adequate cells from masses with abundant acellular matrix [7, 24]. In the indeterminate group, there were six spindle cell lesions, six myxoid-containing tumors, and one well-differentiated liposarcoma. Determining the nature of masses in these categories with FNAC can be difficult and incisional biopsy may be necessary [14, 20, 25, 37, 39]. Pathologists should not be reluctant to request more tissue or to establish minimal criteria for specimen adequacy based on number of unobscured cells per slide [10, 25].
The ability to grade and subtype malignant soft tissue lesions compared favorably with those provided in a limited number of published reports (Table 7). One disadvantage of FNAC compared with NCB and incisional biopsy is the loss of tissue architecture making cytopathologic analysis difficult and specific subtyping less accurate. Ancillary techniques such as immunohistochemistry, cytogenetics, flow cytometry, and electron microscopy are useful if the smear is nondiagnostic [28].
One-fourth of all patients required a secondary biopsy before a definitive management plan was rendered. A previous study analyzed the combination of NCB and FNAC and found 63% were useful to guide treatment and 26.5% required open biopsy [22]. The clinical usefulness of FNAC for evaluation and management of soft tissue masses is based on whether the technique reliably supplies adequate information for initial triage and selection of appropriate therapy. When FNA reveals benign cellular material, the clinician must have confidence in conjunction with clinicoradiographic information to pursue conservative measures or local resection without additional pathologic evaluation. When a malignancy is encountered, the cytopathologist must be able to differentiate high- from low-grade lesions. At most institutions, specific histologic subtyping is not required for treatment to proceed [13, 29]. In certain cases such as high-grade pleomorphic sarcoma, additional specification is unnecessary until another tissue sample is available [35]. Anatomic location, proximity to neurovascular structures, size, and grade determine treatment options. Low-grade malignancies usually can undergo wide excision without neoadjuvant therapy. High-grade malignancies may require chemotherapy or radiation before surgical resection.
Analysis of the discrepant cases revealed seven sampling errors and nine interpretation errors. The ADASP warned the heterogeneity of many soft tissue tumors renders them susceptible to sampling error and misdiagnosis [10]. Contamination from surrounding tissues can occur if cells are aspirated from overlying structures. If the lesion contains cystic, hemorrhagic, or necrotic areas, misrepresentative samples may be aspirated. Specimens from surrounding tissue containing reactive lipocytes, fibroblasts, myofibroblasts, and other cells often have the cytomorphologic appearance of liposarcoma or pleomorphic sarcoma. Pseudosarcomatous proliferations such as nodular fasciitis and pseudomalignant myositis ossificans can have worrisome features and mimic high-grade lesions [26]. Two of the discrepant cases involved relatively rare entities, a large cell Ewing sarcoma, and a pleomorphic hyalinizing angiectatic tumor of soft parts. Recognition of rare tumors and unprecedented new entities can be difficult owing to the lack of published criteria for cytologic diagnosis [7, 32].
FNAC is highly effective in diagnosing malignancy for patients presenting with a palpable soft tissue mass. Nondiagnostic samples and cytologic-histopathologic discrepancies seldom occur with experienced cytopathologists, but close multidisciplinary collaboration can determine when a secondary biopsy is necessary. In most cases, management decisions can be made on the basis of the FNAC and a thorough assessment of the clinicoradiographic presentation.
Acknowledgments
We thank Benjamin Kaffenberger, BS, for assistance with data collection and analysis, Xueliang Jeff Pan, PhD, for statistical analysis, and Carl Morrison, MD, for interpretations of the biopsies.
Footnotes
Each author certifies that he or she has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article.
Each author certifies that his or her institution has approved the human protocol for this investigation and that all investigations were conducted in conformity with ethical principles of research.
1. Akerman M, Rydholm A, Persson BM. Aspiration cytology of soft-tissue tumors: the 10-year experience at an orthopedic oncology center. Acta Orthop Scand. 1985;56:407–412. [PubMed]
2. Barth RJ, Jr, Merino MJ, Solomon D, Yang JC, Baker AR. A prospective study of the value of core needle biopsy and fine needle aspiration in the diagnosis of soft tissue masses. Surgery. 1992;112:536–543. [PubMed]
3. Bauer HC, Trovik CS, Alvegard TA, Berlin O, Erlanson M, Gustafson P, Klepp R, Moller TR, Rydholm A, Saeter G, Wahlstrom O, Wiklund T. Monitoring referral and treatment in soft tissue sarcoma: study based on 1, 851 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand. 2001;72:150–159. [PubMed]
4. Bennert KW, Abdul-Karim FW. Fine needle aspiration cytology vs. needle core biopsy of soft tissue tumors: a comparison. Acta Cytol. 1994;38:381–384. [PubMed]
5. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med. 2005;353:701–711. doi: 10.1056/NEJMra041866. [PubMed] [Cross Ref]
6. Dey P, Mallik MK, Gupta SK, Vasishta RK. Role of fine needle aspiration cytology in the diagnosis of soft tissue tumours and tumour-like lesions. Cytopathology. 2004;15:32–37. doi: 10.1046/j.0956-5507.2003.00102.x. [PubMed] [Cross Ref]
7. Domanski HA. Fine-needle aspiration cytology of soft tissue lesions: diagnostic challenges. Diagn Cytopathol. 2007;35:768–773. doi: 10.1002/dc.20765. [PubMed] [Cross Ref]
8. Domanski HA, Akerman M, Carlen B, Engellau J, Gustafson P, Jonsson K, Mertens F, Rydholm A. Core-needle biopsy performed by the cytopathologist: a technique to complement fine-needle aspiration of soft tissue and bone lesions. Cancer. 2005;105:229–239. doi: 10.1002/cncr.21154. [PubMed] [Cross Ref]
9. Fleshman R, Mayerson J, Wakely PE., Jr Fine-needle aspiration biopsy of high-grade sarcoma: a report of 107 cases. Cancer. 2007;111:491–498. doi: 10.1002/cncr.23122. [PubMed] [Cross Ref]
10. Fletcher CD, Kempson RL, Weiss SW. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of soft tissue sarcoma. Virchows Arch. 1999;434:187–191. doi: 10.1007/s004280050326. [PubMed] [Cross Ref]
11. Gonzalez-Campora R. Fine needle aspiration cytology of soft tissue tumors. Acta Cytol. 2000;44:337–343. [PubMed]
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. doi: 10.3322/CA.2007.0010. [PubMed] [Cross Ref]
13. Jones C, Liu K, Hirschowitz S, Klipfel N, Layfield LJ. Concordance of histopathologic and cytologic grading in musculoskeletal sarcomas: can grades obtained from analysis of fine-needle aspirates serve as the basis for therapeutic decisions? Cancer. 2002;96:83–91. doi: 10.1002/cncr.10479. [PubMed] [Cross Ref]
14. Kilpatrick SE, Bergman S, Pettenati MJ, Gulley ML. The usefulness of cytogenetic analysis in fine needle aspirates for the histologic subtyping of sarcomas. Mod Pathol. 2006;19:815–819. [PubMed]
15. Kilpatrick SE, Cappellari JO, Bos GD, Gold SH, Ward WG. Is fine-needle aspiration biopsy a practical alternative to open biopsy for the primary diagnosis of sarcoma? Experience with 140 patients. Am J Clin Pathol. 2001;115:59–68. doi: 10.1309/YN14-K8U4-5FLJ-DGJE. [PubMed] [Cross Ref]
16. Layfield LJ, Anders KH, Glasgow BJ, Mirra JM. Fine-needle aspiration of primary soft-tissue lesions. Arch Pathol Lab Med. 1986;110:420–424. [PubMed]
17. Liu K, Layfield LJ, Coogan AC, Ballo MS, Bentz JS, Dodge RK. Diagnostic accuracy in fine-needle aspiration of soft tissue and bone lesions: influence of clinical history and experience. Am J Clin Pathol. 1999;111:632–640. [PubMed]
18. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. For the Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am. 1996;78:656–663. [PubMed]
19. Miralles TG, Gosalbez F, Menendez P, Astudillo A, Torre C, Buesa J. Fine needle aspiration cytology of soft-tissue lesions. Acta Cytol. 1986;30:671–678. [PubMed]
20. Nagira K, Yamamoto T, Akisue T, Marui T, Hitora T, Nakatani T, Kurosaka M, Ohbayashi C. Reliability of fine-needle aspiration biopsy in the initial diagnosis of soft-tissue lesions. Diagn Cytopathol. 2002;27:354–361. doi: 10.1002/dc.10200. [PubMed] [Cross Ref]
21. Nasuti JF, Gupta PK, Baloch ZW. Diagnostic value and cost-effectiveness of on-site evaluation of fine-needle aspiration specimens: review of 5, 688 cases. Diagn Cytopathol. 2002;27:1–4. doi: 10.1002/dc.10065. [PubMed] [Cross Ref]
22. Ogilvie CM, Tolbert JT, Finstein JL, Fox EJ, Lackman RD. Clinical utility of percutaneous biopsy of musculoskeletal tumors. Clin Orthop Relat Res. 2006;450:95–100. doi: 10.1097/01.blo.0000229302.52147.c7. [PubMed] [Cross Ref]
23. Oland J, Rosen A, Reif R, Sayfan J, Orda R. Cytodiagnosis of soft tissue tumors. J Surg Oncol. 1988;37:168–170. doi: 10.1002/jso.2930370307. [PubMed] [Cross Ref]
24. Orell SR. Pitfalls in fine needle aspiration cytology. Cytopathology. 2003;14:173–182. doi: 10.1046/j.1365-2303.2003.00078.x. [PubMed] [Cross Ref]
25. Palmer HE, Mukunyadzi P, Culbreth W, Thomas JR. Subgrouping and grading of soft-tissue sarcomas by fine-needle aspiration cytology: a histopathologic correlation study. Diagn Cytopathol. 2001;24:307–316. doi: 10.1002/dc.1067. [PubMed] [Cross Ref]
26. Plaza JA, Mayerson J, Wakely PE., Jr Nodular fasciitis of the hand: a potential diagnostic pitfall in fine-needle aspiration cytopathology. Am J Clin Pathol. 2005;123:388–393. doi: 10.1309/PWD0HB511L3VR56W. [PubMed] [Cross Ref]
27. Rubin M, Horiuchi K, Joy N, Haun W, Read R, Ratzer E, Fenoglio M. Use of fine needle aspiration for solid breast lesions is accurate and cost-effective. Am J Surg. 1997;174:694–696. doi: 10.1016/S0002-9610(97)00192-X. [PubMed] [Cross Ref]
28. Sapi Z, Antal I, Papai Z, Szendroi M, Mayer A, Jakab K, Pajor L, Bodo M. Diagnosis of soft tissue tumors by fine-needle aspiration with combined cytopathology and ancillary techniques. Diagn Cytopathol. 2002;26:232–242. doi: 10.1002/dc.10096. [PubMed] [Cross Ref]
29. Singh HK, Kilpatrick SE, Silverman JE. Fine needle aspiration biopsy of soft tissue sarcomas: utility and diagnostic challenges. Adv Anat Pathol. 2004;11:24–37. doi: 10.1097/00125480-200401000-00003. [PubMed] [Cross Ref]
30. Skrzynski MC, Biermann JS, Montag A, Simon MA. Diagnostic accuracy and charge-savings of outpatient core needle biopsy compared with open biopsy of musculoskeletal tumors. J Bone Joint Surg Am. 1996;78:644–649. [PubMed]
31. Springfield DS, Rosenberg A. Biopsy: complicated and risky. J Bone Joint Surg Am. 1996;78:639–643. [PubMed]
32. Suster D, Plaza JA, Shen R. Low-grade malignant perineurioma (perineurial sarcoma) of soft tissue: a potential diagnostic pitfall on fine needle aspiration. Ann Diagn Pathol. 2005;9:197–201. doi: 10.1016/j.anndiagpath.2005.04.016. [PubMed] [Cross Ref]
33. Trovik CS. Local recurrence of soft tissue sarcoma. A Scandinavian Sarcoma Group Project. Acta Orthop Scand Suppl. 2001;72:1–31. doi: 10.1080/000164701753606608. [PubMed] [Cross Ref]
34. Trovik CS, Bauer HC, Brosjo O, Skoog L, Soderlund V. Fine needle aspiration (FNA) cytology in the diagnosis of recurrent soft tissue sarcoma. Cytopathology. 1998;9:320–328. doi: 10.1046/j.1365-2303.1998.00102.x. [PubMed] [Cross Ref]
35. Wakely PE, Jr, Kneisl JS. Soft tissue aspiration cytopathology. Cancer. 2000;90:292–298. doi: 10.1002/1097-0142(20001025)90:5<292::AID-CNCR5>3.0.CO;2-8. [PubMed] [Cross Ref]
36. Wakely PE, Jr, Powers CW, Frable WJ. Metachronous soft-tissue masses in children and young adults with cancer: correlation of histology and aspiration cytology. Hum Pathol. 1990;21:669–677. doi: 10.1016/S0046-8177(96)90015-5. [PubMed] [Cross Ref]
37. Ward WG, Savage P, Boles CA, Kilpatrick SE. Fine-needle aspiration biopsy of sarcoma and related tumors. Cancer Control. 2001;8:232–238. [PubMed]
38. Willen H, Akerman M, Carlen B. Fine needle aspiration (FNA) in the diagnosis of soft tissue tumours; a review of 22 years experience. Cytopathology. 1995;6:236–247. doi: 10.1111/j.1365-2303.1995.tb00475.x. [PubMed] [Cross Ref]
39. Yang YJ, Damron TA. Comparison of needle core biopsy and fine-needle aspiration for diagnostic accuracy in musculoskeletal lesions. Arch Pathol Lab Med. 2004;128:759–764. [PubMed]
Articles from Clinical Orthopaedics and Related Research are provided here courtesy of
The Association of Bone and Joint Surgeons